Tardive dyskinesia: An update

Drugs of Today

Volumn 37, Issue 2, 2001, Pages 97-119

  Kulkarni, S K ^a   Naidu, P S ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIEMETIC AGENT; ANTIHISTAMINIC AGENT; ANTIOXIDANT; ANTIPARKINSON AGENT; ANXIOLYTIC AGENT; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOGENIC AMINE; CALCIUM CHANNEL BLOCKING AGENT; CENTRAL STIMULANT AGENT; CHLORPROMAZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINERGIC RECEPTOR STIMULATING AGENT; CLOZAPINE; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; HALOPERIDOL; ISONIAZID; LOXAPINE; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; NEUROPEPTIDE; ORAL CONTRACEPTIVE AGENT; RESERPINE; SEROTONIN AGONIST; SEROTONIN UPTAKE INHIBITOR; TRANQUILIZER; TRICYCLIC ANTIDEPRESSANT AGENT;

ANTICHOLINERGIC EFFECT; BASAL GANGLION; BINDING AFFINITY; CALCIUM SIGNALING; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE SEVERITY; DOPAMINERGIC SYSTEM; DOSE RESPONSE; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG WITHDRAWAL; GABAERGIC SYSTEM; GENETIC PREDISPOSITION; HUMAN; NEUROTRANSMISSION; NONHUMAN; NORADRENERGIC SYSTEM; OROFACIAL DYSKINESIA; OXIDATIVE STRESS; PATHOPHYSIOLOGY; REVIEW; SCHIZOPHRENIA; SEROTONINERGIC SYSTEM; SIGNAL TRANSDUCTION; TARDIVE DYSKINESIA; TREATMENT PLANNING;

EID: 0035071894     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2001.37.2.834327     Document Type: Review

References (207)

1. Thirty-eight cases of psychosis caused by the prolonged and continuous use of RP4560
2. Tardive dystonia: Prevalence, risk factors and comparison with tardive dsykinesia in a population of two hundred acute psychiatric patients
3. The identification and management of drug-induced akathesia
4. Tardive dyskinesia: Pathophysiology
5. A rare syndrome after oral administration of Megaphen
6. Persistent muscular restlessness after phenothiazine treatment: Report of three cases
7. An apparently irreversible syndrome of abnormal movements following phenothiazine medication
8. Neurological symptoms in pharmacotherapy in psychosis
9. History and definition of tardive dsykinesia
10. Tardive dyskinesia as fife-threatening illness
11. Spontaneous involuntary disorders of movement
12. Abnormal involuntary movements and psychosis in the preneuroleptic era and in unmedicated patients: Implications for the concept of tardive dyskinesia
13. Tardive dyskinesia: Epidemiological and clinical presentation
14. Dyskinesias associated with tricyclic antidepressants
15. Oral-buccal dyskinesia symptoms associated with low-dose benzodiazepine treatment
16. Anticonvulsant-induced dyskinesias: A comparison with dyskinesias induced by neuroleptics
17. Neuroleptic-induced dyskinesia in children
18. Implications of amphetamine-induced stereotypy as a model for tardive dyskinesia
19. Extrapyramidal reactions with metoclopramide
20. 1 antihistaminic medications
21. Risk factors for spontaneous dyskinesia in schizophrenia
22. Tardive dyskinesia
23. Tardive dyskinesia
24. Gender differences in tardive dyskinesia: A critical review of the literature
25. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications
26. Predicting the long-term risk of tardive dyskinesia in out-patients maintained on neuroleptic medications
27. 2 receptors and neuropeptides in striatonigral and striatopallidal neurons of rat with neuroleptic-induced dyskinesias
28. Treatment of tardive dyskinesia
29. Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia
30. Neurotoxicity associated with neuroleptic induced oral dyskinesias in rats: Implications for tardive dyskinesia?
31. Tardive dyskinesia: Pathophysiology and animal models
32. Neurotransmitters and neuromodulators in the basal ganglia
33. Primate models of movement disorders of basal ganglia origin
34. Functional anatomy of the basal ganglia. I. The cortico-basal ganglia-thalamo-cortical loop
35. Efferent connections of the centromedian and parafascicular thalamic nuclei in the squirrel monkey: A PHA-L study of subcortical projections
36. The pedunculopontine nucleus in the squirrel monkey: Projections to the basal ganglia as revealed by anterograde tract tracing methods
37. Pathophysiology of parkinsonian motor abnormalities
38. Theoretical implications of the use of L-dopa in parkinsonism
39. Tardive dyskinesia
40. Spontaneous orofacial movements induced in rodents with very long-term neuroleptic drug administration: Phenomenology, pathophysiology and putative relationship to tardive dyskinesia
41. Neurobiological substrates of tardive dsykinesia: The GABA hypothesis
42. 2 receptors
43. Clozapine: Neuroleptic-induced EPS and tardive dyskinesia
44. 2 agonist on oral movements in rats
45. 2 receptor antagonists on oral activity in rats
46. 1 receptors in the sub-commisural part of globus pallidus and their role in orofacial dyskinesia in cats
47. 1 stimulation
48. Persistent vacuous chewing in rats following neuroleptic treatment: Relationship to dopaminergic and cholinergic function
49. Spontaneous chewing movements in rats during acute and chronic antipsychotic drug administration
50. Haloperidol-induced vacuous chewing in rats: Suppression by α-methyl-tyrosine
51. 2 receptor agonists in monkeys previously treated with haloperidol
52. Intermittent versus continuous neuroleptic treatment in a rat model
53. The functional neuroanatomy of the basal ganglia disorders
54. Interactions between glutamatergic and monoaminergic systems within the basal ganglia - Implications for schizophrenia and Parkinson's disease
55. A hypothesis on the pathophysiological mechanisms that underlie levodopa or dopamine agonist-induced dyskinesia in Parkinson's disease: Implications for future strategies in treatment
56. Neurotransmitters and epilepsy
57. Spontaneous orofacial dyskinesia and dopaminergic function in rats after six months of neuroleptic treatment
58. Neurology 2: Movement disorders
59. Regulation of GABA synthesis in the brain
60. Evidence for cell loss in corpus striatum after long-term treatment with a neuroleptic drug (flupenithixol) in rats
61. Association with persistent neuroleptic-induced dyskinesia of regional changes in brain GABA synthesis
62. Methyl azo methanol (MAM)-induced brain lesion and oral dyskinesia in rats
63. Expression of glutamic acid decarboxylase mRNA in striatum and pallidum in an animal model of tardive dyskinesia
64. Brain gamma-aminobutyric acid abnormality in tardive dsykinesia. Reduction in cerebrospinal fluid GABA levels and therapeutic response to GABA agonist treatment
65. Oral movements induced by interference with nigral GABA neurotransmission: Relationship to tardive dyskinesias
66. Improvement in tardive dsykinesia after muscimol therapy
67. Co-administration of progabide inhibits haloperidol-induced oral dyskinesia in rats
68. Tigabine inhibits haloperidol-induced oral dyskinesias in rats
69. Suppression of haloperidol-induced oral dyskinesias in rats by vigabatrin
70. Reduced glutamate decarboxylase activity in the subthalamic nucleus in patients with tardive dyskinesia
71. Effect of gamma-vinyl-GABA in tardive dyskinesia
72. Clonazepam treatment of tardive dyskinesia: A practical GABAmimetic strategy
73. Receptor selectivities of atypical neuroleptics
74. 2-receptor occupancy in clozapine treated patients
75. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients
76. Risperidone in the treatment of patients with chronic schizophrenia: A multinational, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group
77. Chronic treatment with clozapine or haloperidol differentially regulates dopamine and serotonin receptors in rat brain
78. PET analysis indicates atypical central dopamine receptors occupancy in clozapine-treated patients
79. Serotonergic mechanisms in neuroleptic-induced catalepsy in the rat
80. 2A/C antagonist, reverse haloperidol-induced catalepsy in rats independently of striatal dopamine release
81. The pharmacological characterization of pilocarpine-induced purposeless chewing behavior in the rat
82. 1 dopamine receptor mediated grooming behavior
83. 2C-induced oral dyskinesia
84. Dopaminergic stimulation of subthalamic nucleus elicits oral dyskinesia in rats
85. 1C receptor mRNA in the basal ganglia of rats
86. 1C receptor mRNA in the rodent brain examined by in situ hybridization histochemistry. Comparison with receptor binding distribution
87. Psychogenicity and N-methyl-D-aspartate receptor antagonism: Implications for neuroprotective pharmacotherapy
88. Duplication of biochemical changes of Huntington's chorea by intrastriatal injections of glutamic and kinic acids
89. Excitotoxic mechanisms may be involved in the pathophysiology of tardive dyskinesia
90. An animal model for coexisting tardive dyskinesia and tardive parkinsonism: A glutamate hypothesis for tardive dyskinesia
91. Haloperidol-induced morphological changes in striatum are associated with glutamate synapse
92. Duration-dependent increase in striatal glutamate following prolonged fluphenazine administration in rats
93. Haloperidol interacts with the strychnine-insensitive glycine site at the NMDA receptor in cultured mouse hippocampal neurons
94. Chronic antipsychotic treatment alters glycine-stimulated NMDA receptor binding in rat brain
95. Regulation of cortical and subcortical glutamate receptor subunit expression by antipsychotic drugs
96. Differential regulation of hippocampal AMPA and kainate receptor subunit expression by haloperidol and clozapine
97. Differential effects of chronic antipsychotic drug treatment on extracellular glutamate and dopamine concentrations
98. Antipsychotic drug effects on glutamatergic activity
99. Anti-glutamatergic effects of clozapine
100. Memantine inhibits the development of haloperidol-induced persistent oral movements
101. Effect of MK-801 on the prevention and treatment of vacuous chewing in rats
102. Dopaminergic modulation of NMDA-induced whole cell currents in neostriatal neurons in slices: Contribution of calcium conductances
103. 1 dopaminergic protein kinase/phosphatase cascade in rat neostriatal neurons
104. 1 dopamine receptors through a cAMP/protein kinase A-dependent mechanism
105. Dopamine modulation of NMDA-induced calcium transients in fetal neocortical cultures and dissociated neostriatal neurons
106. Dopamine and N-methyl-D-aspartate receptor interactions in the neostriatum
107. Effects of nifedipine, a calcium channel antagonist on cognitive function in schizophrenic patients with tardive dyskinesia
108. Isolation of nitric oxide synthetase, a calmodulin-requiring enzyme
109. NMDA receptor activation induces nitric oxide synthesis from arginine in rat brain slices
110. Formation of nitric oxide from L-arginine in the central nervous system: A transduction mechanism for stimulation of the soluble guanylate cyclase
111. Endothelium-derived relaxing factor release on activation of NMDA receptors suggests role as intercellular messenger in the brain
112. Induction and variants of neuronal nitric oxide synthase type I during synaptogesis
113. Nitric oxide mediates glutamate neurotoxicity in primary cortical cultures
114. Cloned and expressed nitric oxide synthase structurally resembles cytochrome P450 reductase
115. Nitric oxide and synaptic function
116. Biphasic modulation of GABA release by nitric oxide in the hippocampus of freely moving rats in vivo
117. 3H]-dopamine from striatal slices
118. Role of nitric oxide in modulating neurotransmitter release from rat striatum
119. Role of nitric oxide in modulating the release of dopamine, glutamate, and GABA in striatum of the freely moving rat
120. N-methyl-D-aspartate stimulates dopamine release through nitric oxide formation in the nucleus accumbens of rats
121. Effect of nitroprusside (nitric oxide) on endogenous dopamine release from rat striatal slices
122. Nitric oxide involvement in regulating the dopamine transport in the striatal region of rat brain
123. A possible role of nitric oxide in the regulation of dopamine transporter function in the striatum
124. In vivo effects of psychotrophic agents on the physical properties of cell membranes in the rat brain
125. Generation of superoxide anion in the reaction of tetrahydropteridines with molecular oxygen
126. The generation of superoxide radicals during the autooxidation of ferrodoxins
127. Free radical mechanism in schizophrenia and tardive dyskinesia
128. Free radicals and tardive dyskinesia
129. Oxidative stress, glutamate and neurodegenerative disorders
130. Tardive dyskinesia: Possible involvement of free radicals and treatment with vitamin E
131. Oxygen radicals diminish dopamine transporter function in rat striatum
132. On the metabolism of haloperidol
133. Neuroleptic medications inhibit complex I of the electron transport chain
134. Free radicals and the developmental pathobiology of schizophrenic burnout
135. The prevalence of tardive dyskinesia in a mentally retarded population
136. Effectiveness of vitamin E for treatment of long-term tardive dyskinesia
137. Vitamin E attenuates the development of haloperidol-induced dopaminergic hypersensitivity in rats: Possible implication for tardive dyskinesia
138. The preventive role of antioxidants (selegiline and vitamin E) in a rat model of tardive dyskinesia
139. Response of striatonigral substance P systems to a dopamine receptor agonist and antagonist
140. Substance P content of substantia nigra after chronic treatment with antischizophrenic drugs
141. Intranigral infusion of enkephalins elicits dyskinetic biting in rats
142. 2 receptor antagonists
143. Neuroleptic-induced hypersensitivity of striatal dopamine receptors in the rat as a model of tardive dyskinesias. Effects of clozapine, haloperidol, loxapine and chlorpromazine
144. Multiple calcium channels and neuronal function
145. Differential effects of antipsychotic drugs on the neurotensin concentration of discrete rat brain nuclei
146. Neurotensin and neurotensin analogues modify the effects of chronic neuroleptic administration in the rat
147. 1 receptors
148. Effects of neurotensin in a rodent model of tardive dyskinesia
149. Animal models in psychiatric research
150. A scaling approach to find order parameters quantifying the effects of dopaminergic agents on unconditioned motor activity in rats
151. Animal models of acute drug-induced akathisia: A review
152. Tardive dyskinesia: Animal models
153. Haloperidol-induced tardive dyskinesia in monkeys
154. The effect of chronic neuroleptic administration on cerebral dopamine receptor function
155. Neuroleptic-induced vacuous chewing movements as an animal model of tardive dyskinesia: A study in three rat strains
156. Chronic olanzapine or sertindole treatment results in reduced oral chewing movements in rats compared to haloperidol
157. Cerebral dopamine function in rats following withdrawal from one year of continuous neuroleptic administration
158. The lifetime outcome and involuntary movements of schizophrenia never treated with neuroleptic drugs
159. Oral dyskinesia in brain damaged rats withdrawn from a neuroleptic: Implications for models of tardive dyskinesia
160. Oral dyskinesia in rats following brain lesions and neuroleptic drug administration
161. Pharmacological characterization of spontaneous or drug-associated purposeless chewing movements in rats
162. Dose-dependent increase in rat spontaneous chewing rates during long-term administration of haloperidol but not clozapine
163. Neuroleptic-induced oral dyskinesias: Effects of progabide and lack of correlation with regional changes in glutamic acid decarboxylase and choline acetyltransferase activities
164. Tremorous mouth movements in rats administered chronic neuroleptics
165. Behavioral consequences of long-term treatment with neuroleptic drugs
166. Reduction of nigral glutamic acid decarboxylase in rats with neuroleptic-induced oral dyskinesia
167. Study on the suitability of a rat model for tardive dsykinesia and the preventive effects of various drugs
168. Rolipram, a selective c-AMP phosphodiesterase inhibitor suppresses oro-facial dyskinetic movements in rats
169. Reversible and irreversible dyskinesias after treatment with perphenazine, chlorpromazine, reserpine and electroconvulsive therapy
170. Behavioral and neurochemical effects of chronic administration of reserpine and SKF38393 in rats
171. Neurochemical changes associated with the persistence of spontaneous oral dyskinesia in rats following chronic reserpine treatment
172. Dose dependent differences in the development of reserpine-induced oral dyskinesia in rats: Support for a model of tardive dyskinesia
173. GABAergic denervation of rat substantia nigra: Functional and pharmacological properties
174. 2 receptors in isoniazid-induced vacuous chewing movements in rats
175. Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia
176. Effects of antioxidant treatment on the VCM syndrome
177. GM1 ganglioside attenuates the development of vacuous chewing movements induced by long-term haloperidol treatment of rats
178. Clozapine and tardive dyskinesia
179. Clozapine treatment of psychosis in patients with tardive dystonia: Report of three cases
180. Reserpine and α-methyldopa in the treatment of tardive dsykinesia
181. Clonidine therapy for tardive dsykinesia and related syndromes
182. Meclofenoxate therapy in tardive dyskinesia: A preliminary report
183. 2 antagonists on haloperidol-induced dyskinesias in squirrel monkeys: No evidence for reciprocal 5-HT-dopamine interaction
184. Cholinergic medication for drug-induced tardive dyskinesia
185. Anti-cholinergic medication for neuroleptic-induced tardive dyskinesia
186. Gamma-Vinyl-GABA treatment of tardive dyskinesia and other movement disorders
187. γ-Aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia
188. Benzodiazepines for neuroleptic-induced tardive dyskinesia
189. A double-blind placebo controlled study of vitamin E treatment of tardive dyskinesia
190. Tardive dyskinesia: Review of treatments past, present, and future
191. Vitamin E for neuroleptic-induced tardive dyskinesia
192. Nifedipine in the treatment of tardive dyskinesia
193. Diltiazem, nifedipine, nimodipine or verapamil for neuroleptic-induced tardive dyskinesia
194. Are calcium channel blockers effective in the treatment of tardive dyskinesia?
195. Serotonin function in tardive dyskinesia
196. Buspirone in the treatment of tardive dyskinesia
197. Fluperlapine in tardive dyskinesia and parkinsonism
198. Treatment of phenothiazine-induced dyskinesia
199. 3 receptor antagonist ondansetron in the treatment of neuroleptic-induced tardive dyskinesia
200. Enkephalin, morphine and nalaxone in tardive dyskinesia
201. Miscellaneous treatments for neuroleptic-induced tardive dyskinesia
202. The effects of lithium on an animal model of tardive dsykinesia
203. Successful treatment of tardive and spontaneous dyskinesias with corticosteroids
204. ECT and tardive dyskinesia